Common Diabetes Drug Not Effective Against Early-Stage Breast Cancer, Landmark Trial Reveals
Research, Partnerships
Courtesy of Sinai Health
Professor Pamela Goodwin
By
Amanda Ferguson
A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new research.
The study, led by Toronto researchers and run by the Canadian Cancer Trials Group under the umbrella of the Breast International Group network, is the largest of its kind to date, tracking more than 3,600 breast cancer patients from across Canada, the U.S., Switzerland and the UK.
The randomized, double-blind trial enrolled patients who were treated with two pills a day of either placebo or the diabetes drug metformin. Overall, researchers found the addition of metformin to standard breast cancer treatments did not improve outcomes in the two most common types of breast cancer, hormone receptor-positive or negative.
“The results tell us that metformin is not effective against the most common types of breast cancer and any off-label use of this drug for the treatment of these common types of breast cancer should be stopped,” said Pamela Goodwin, a professor in the department of medicine at University of Toronto’s Temerty Faculty of Medicine, who also is a medical oncologist at Sinai Health and a clinician scientist at the Lunenfeld-Tanenbaum Research Institute.
While metformin was found not to be effective in treating the most common forms of breast cancer, Goodwin said the trial found a potentially important result for individuals with a less common but aggressive form of the disease, called HER2-positive breast cancer.
For this subtype of breast cancer, researchers found there was evidence that use of metformin for five years might lead to a reduction in deaths. HER2-positive cancer makes up about 20 per cent of all breast cancers.
“These results need to be replicated in future research before metformin is used as a breast cancer treatment, however, it could provide an additional treatment option for HER2-positive breast cancer,” said Goodwin.
Metformin belongs to a class of drugs called biguanides, which are used to treat high blood sugar or diabetes. Previous observational and pre-clinical studies suggested metformin may also reduce the risk of development and increase survival of some cancers, including breast cancer.
It was theorized the drug may slow breast cancer growth by improving patient metabolism, notably insulin levels, leading to reduced growth of cancer cells, or that it might impact cancer cells directly.
The results have been submitted for publication. A potential next step will be to prospectively test the impact of metformin in patients with HER2-positive breast cancer in a randomized clinical trial.
The multinational trial involved a large team of scientists including Goodwin and Vuk Stambolic, a professor of medical biophysics at U of T and at senior scientist at the Princess Margaret Cancer Centre, University Health Network.
Professors Wendy Parulekar and Bingshu Chen of Queen's University and the Canadian Cancer Trials Group were also involved with the study.
The research was funded by the Canadian Cancer Society Research Institute, National Cancer Institute (U.S.), Canadian Breast Cancer Foundation, Breast Cancer Research Foundation, Cancer Research UK, Hold’Em for Life Charity Challenge and Apotex (Canada).
A new approach for early cancer treatment known as radioligand therapy has been shown to reduce the risk of advanced neuroendocrine tumour progression and death by 72 per cent in otherwise challenging areas to treat.
The University of Toronto and the Centre for Addiction and Mental Health have received over $3 million to advance and commercialize radiopharmaceutical technologies for health care, and to train a new generation of scientists and clinicians.
A generous new donation from the Hold’em for Life Charity Challenge has established 12 new professorships for early-career clinician-scientists working in a broad range of cancer-related fields at U of T-affiliated hospitals across Toronto.